相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2010
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- GenFleet Therapeutics has dosed the first patient in Kylin-Flight 01, the first registrational Phase III study of an oral KRAS G12D inhibitor in non-small cell lung cancer. - The multicenter, open-label, randomized trial will compare GFH375 monotherapy against docetaxel in KRAS G12D-mutant NSCLC patients who have failed standard therapy across over 40 sites in China. - Phase I/II data presented at WCLC 2025 showed a 68.8% overall response rate at the recommended Phase II dose of 600 mg once daily, with a disease control rate of 93.8%. - GFH375 has received China's first two breakthrough therapy designations for a KRAS G12D inhibitor, covering both NSCLC and pancreatic cancer, where a separate registrational trial is also underway.
- JingFang Medicine-B's oral KRAS G12D inhibitor GFH375 has been granted China's first Breakthrough Therapy Designation for treating KRAS G12D-mutated non-small cell lung cancer patients who have received at least one systemic treatment. - Phase I/II trial data from the GFH375X1101 study demonstrated best-in-class efficacy for GFH375 monotherapy in KRAS G12D-mutated NSCLC with manageable safety and tolerability profiles. - The designation addresses a significant unmet medical need, as no KRAS G12D-targeted therapies are currently approved globally across various tumor types with G12D mutations. - GFH375 leads globally in clinical development progress for treating NSCLC among KRAS G12D inhibitors currently in development, with multiple monotherapy and combination studies proceeding both domestically and internationally.
- Artios Pharma appointed three senior executives to strengthen late-stage development capabilities as the company advances its DNA Damage Response pipeline toward commercialization. - Roy W. Ware joins as Chief Manufacturing and Technology Officer, bringing over 20 years of experience in advancing first-in-class oncology programs through FDA approval. - The leadership team will support the advancement of alnodesertib into late-stage development and potential U.S. commercialization while executing Phase 2 studies for ART6043. - These appointments establish integrated capabilities across manufacturing, clinical operations, and medical affairs to accelerate delivery of potential first-in-class DDR medicines to cancer patients.
- Verastem Oncology announced discontinuation of the RAMP 203 Phase 1/2 trial testing combination therapy in KRAS G12C-mutated non-small cell lung cancer following interim data evaluation. - The company will redirect resources to VS-7375, an oral KRAS G12D inhibitor that demonstrated a 69% response rate in advanced KRAS G12D NSCLC patients. - RAMP 203 showed modest efficacy with 40% response rate in treatment-naïve patients but only 9.5% in previously treated patients with existing G12C inhibitors. - The strategic shift reflects the evolving treatment landscape where next-generation G12C inhibitors are establishing higher response rate benchmarks.
- Verastem Oncology appointed Michael Kauffman, M.D., Ph.D., as president of development and John Johnson as chairman of the board to accelerate growth following successful launch of AVMAPKI FAKZYNJA CO-PACK for rare ovarian cancer. - The company completed additional patient enrollment for RAMP 301, its Phase 3 confirmatory trial evaluating the combination therapy in recurrent low-grade serous ovarian cancer, with topline data expected in mid-2027. - Kauffman will focus on advancing VS-7375, described as a potential best-in-class KRAS G12D dual ON/OFF inhibitor that could transform outcomes for patients with limited treatment options.
- Tempus AI and Verastem Oncology have announced a collaboration to develop a companion diagnostic test for the recently FDA-approved combination therapy of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. - The partnership builds on Tempus' confirmatory testing in Verastem's Phase 2 RAMP-201 clinical trial, with their FDA-approved xT CDx assay now being used as an investigational assay in the global Phase 3 RAMP-301 trial. - Low-grade serous ovarian cancer (LGSOC) is a rare form affecting younger women, accounting for 6-10% of serous ovarian cancers, with historically poor response to chemotherapy and limited treatment options.
- Researchers have identified a promising combination therapy using FAK inhibitors with RAF-MEK clamps that effectively overcomes treatment resistance in BRAF V600E-mutated melanoma. - The dual-targeting approach not only treats existing brain metastases but also prevents melanoma cells from spreading to the brain, addressing a critical unmet need for patients with limited treatment options. - This oral combination therapy of defactinib (FAK inhibitor) and avutometinib (RAF-MEK inhibitor) could improve accessibility for melanoma patients in rural areas who struggle to access infusion-based immunotherapies.
- Verastem Oncology will present additional analyses from the Phase 2 RAMP 201 trial evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2025, building on their FDA Priority Review submission. - The presentations include new subgroup analyses by KRAS mutational status, supporting the company's ongoing efforts to advance treatment options for RAS/MAPK pathway-driven cancers. - The company's NDA for the avutometinib-defactinib combination therapy has received Priority Review from the FDA with a PDUFA date of June 30, 2025, for KRAS mutant LGSOC patients.
- Verastem Oncology secured a new credit facility of up to $150 million and a $7.5 million equity investment with Oberland Capital, refinancing existing debt with Oxford Finance. - A strategic collaboration with IQVIA aims to accelerate the commercial launch of the avutometinib and defactinib combination for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). - The FDA granted priority review with a PDUFA date of June 30, 2025, for the NDA of avutometinib and defactinib in recurrent KRAS mutant LGSOC after prior systemic therapy. - Verastem exercised its option to license VS-7375, a KRAS G12D inhibitor, from GenFleet Therapeutics, with preliminary Phase 1 data from China showing promise.
- The FDA has granted Priority Review to Verastem Oncology's NDA for avutometinib combined with defactinib for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). - The PDUFA target action date is set for June 30, 2025, with the FDA indicating that an advisory committee meeting is not currently planned. - The NDA is supported by Phase 2 RAMP 201 trial data, demonstrating substantial overall response rates and durable responses in patients with recurrent KRAS mutant LGSOC. - If approved, this combination therapy would be the first FDA-approved treatment specifically for adults with recurrent KRAS mutant LGSOC, addressing a significant unmet need.
